Meningococcal serogroup B vaccines: will they live up to expectations?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.Vaccines · 2019
   Article
2. Meningococcal B vaccine and the vision of a meningitis free world.Journal of preventive medicine and hygiene · 2015
   Review
3. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.Drugs · 2014
   Review
4. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.Human vaccines & immunotherapeutics · 2013
   Article
5. Adjuvant efficacy of mOMV against avian influenza virus infection in mice.Journal of microbiology (Seoul, Korea) · 2013
   Article
6. Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.PloS one · 2013
   Article
7. Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.PloS one · 2013
   Article
8. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.PloS one · 2013
   Article
9. Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.Acta crystallographica. Section F, Structural biology and crystallization communications · 2012
   Article
10. Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as